Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
Arthritis Res Ther. 2020 Jun 9;22(1):137.
doi: 10.1186/s13075-020-02238-4.